Intervention

RPL554

ClinicalTrials.gov intervention label

Clinical trials3

Recruiting0

Common conditions4

Lead sponsors shown1

Clinical trials

3 shown

The Effects of RPL554 on Top of Standard COPD Reliever MedicationsNCT02542254 · 2015-10-01

Comparison of RPL554 With Placebo and Salbutamol in Asthmatic PatientsNCT02427165 · 2015-04-01

SAD/MAD Study of a New Formulation of Nebulised RPL554 in Healthy Subjects and COPD SubjectsNCT02307162 · 2014-12-01

Common conditions

Asthma1 Chronic Obstructive Pulmonary Disease1 Chronic Obstructive Pulmonary Disorder1 Inflammatory Disorder of the Respiratory Tract1

Leading sponsors

Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA3

Trial status mix

COMPLETED3

Phase mix

PHASE22

PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.